|Bid||39.50 x 1200|
|Ask||39.53 x 900|
|Day's Range||39.05 - 39.87|
|52 Week Range||29.99 - 43.08|
|Beta (5Y Monthly)||0.67|
|PE Ratio (TTM)||20.05|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||1.56 (3.94%)|
|Ex-Dividend Date||May 06, 2021|
|1y Target Est||41.99|
In this video from Motley Fool Live, recorded on April 5, Fool.com Contributors Brian Orelli and Keith Speights discuss a question from a member named Angel, who asks whether Viatris (NASDAQ: VTRS) is worth holding. The duo discuss Viatris' prospects and the type of investor that is most appropriate for holding the generic-drug maker. Keith Speights: Is Viatris, the ticker there's VTRS, a keeper.
• As of Sunday, the U.S. has reported 581,572 deaths from Covid-19, but that number is likely an undercount, Dr. Anthony Fauci told NBC’s “Meet the Press” on Sunday, referring to the tally from Johns Hopkins University. “I think there’s no doubt that we are and have been undercounting,” said Fauci, who is the director of the National Institute of Allergy and Infectious Diseases. When asked if the actual number could be more than 900,000, as estimated last week by the University of Washington, Fauci said that bigger number is “a bit more than I would have thought the undercounting was.”
The European Union has not made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday, after the EU signed a deal with Pfizer-BioNTech. Breton also said he expected the costs of the Pfizer-BioNTech vaccines to be higher than the earlier versions. The Commission last month launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries.